Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, Richardson W, Towne P, Hanks D, Vennapusa B, Mistry A, Kalamegham R, Averbuch S, Novotny J, Rubin E, Emancipator K, McCaffery I, Williams JA, Walker J, Longshore J, Tsao MS, Kerr KM. Hirsch FR, et al. Among authors: vennapusa b. J Thorac Oncol. 2017 Feb;12(2):208-222. doi: 10.1016/j.jtho.2016.11.2228. Epub 2016 Nov 29. J Thorac Oncol. 2017. PMID: 27913228 Free article. Clinical Trial.
Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab.
Vennapusa B, Baker B, Kowanetz M, Boone J, Menzl I, Bruey JM, Fine G, Mariathasan S, McCaffery I, Mocci S, Rost S, Smith D, Dennis E, Tang SY, Damadzadeh B, Walker E, Hegde PS, Williams JA, Koeppen H, Boyd Z. Vennapusa B, et al. Appl Immunohistochem Mol Morphol. 2019 Feb;27(2):92-100. doi: 10.1097/PAI.0000000000000594. Appl Immunohistochem Mol Morphol. 2019. PMID: 29346180 Free PMC article.
Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer.
Li Y, Vennapusa B, Chang CW, Tran D, Nakamura R, Sumiyoshi T, Hegde P, Molinero L. Li Y, et al. Among authors: vennapusa b. Appl Immunohistochem Mol Morphol. 2021 Apr 1;29(4):258-264. doi: 10.1097/PAI.0000000000000857. Appl Immunohistochem Mol Morphol. 2021. PMID: 33030848 Free PMC article. Clinical Trial.
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA 3rd, Robert F, Han TH, Bheddah S, Theiss N, Watson S, Mathur D, Vennapusa B, Zayed H, Lally S, Strickland DK, Govindan R, Dylla SJ, Peng SL, Spigel DR; SCRX16-001 investigators. Rudin CM, et al. Among authors: vennapusa b. Lancet Oncol. 2017 Jan;18(1):42-51. doi: 10.1016/S1470-2045(16)30565-4. Epub 2016 Dec 5. Lancet Oncol. 2017. PMID: 27932068 Free PMC article. Clinical Trial.
15 results